Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
Eisai and Cogstate announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate for use in healthcare and other markets.
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment
Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.
A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA).
Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program
Cogstate today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly increase the speed and quality of Alzheimer’s clinical trials.
Cogstate today announced it has been chosen as the preferred provider to Eli Lilly and Company to support their Alzheimer’s disease platform with solutions to ensure high-quality neuropsychological outcome measures in clinical trials.